Article Sidebar

PDF
Issue: Vol. 567 No. 1 (2026)
Section: Các bài báo
DOI: 10.51298/vmj.v567i1.19278
Date Published: 05/11/2026
Views 41
Downloads 24
How to Cite
Nguyễn, T. K. Y., Huỳnh, N. T., Nguyễn, N. S., Hoàng, T. T. N., & Nguyễn, P. L. (2026). UTILITY OF CD200 IN THE DIFFERENTIAL DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA. Vietnam Medical Journal, 567(1). https://doi.org/10.51298/vmj.v567i1.19278

UTILITY OF CD200 IN THE DIFFERENTIAL DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA

Thị Kim Yến Nguyễn1, , Nhật Toàn Huỳnh2, Ngọc Sang Nguyễn1, Thị Tuệ Ngọc Hoàng1, Phương Liên Nguyễn1
1 Bệnh viện Truyền máu Huyết học
2 Bệnh viện Đa khoa Bình Thuận

Main Article Content

Abstract

Objectives: To evaluate the diagnostic value of CD200 in distinguishing B-CLL from MCL and to describe the immunophenotypic features of both entities.


Study Design: Case series descriptive study.


Setting: The study was conducted at Ho Chi Minh City Blood Transfusion Hematology Hospital from June 2020 to August 2023.


Participants: A total of 85 patients diagnosed with B-CLL or MCL were included, comprising 70 cases of B-CLL and 15 cases of MCL.


Results: CD200 was positive in 100% of B-CLL cases and 13.3% of MCL cases (p<0.001). CD43 expression was significantly higher in B-CLL (87.1% vs 26.7%; p<0.001). In contrast, CD79b, FMC7, and monoclonal light-chain restriction were more frequent in MCL (p<0.05). No significant differences were observed for CD5, CD20, CD22, or CD23.


Conclusions: CD200 is a valuable immunophenotypic marker for distinguishing B-CLL from MCL. Combining CD200 with CD43, CD79b, FMC7, and light-chain restriction may improve the diagnostic accuracy of mature B-cell lymphoproliferative disorders.

Keywords

CD200, B-CLL, mantle cell lymphoma, flow cytometry

Article Details

References

1. Choi SM, O’Malley DP. Diagnostically relevant updates to the 2017 WHO classification of lymphoid neoplasms. Ann Diagn Pathol. 2018;37:67-74.
2. Monabati A, Safaei A, Mokhtari M, et al. Mantle cell lymphoma: pathologic and immunophenotyping study of 50 cases and correlation with survival—a single institute experience. J Hematopathol. 2020;13(3):153-158.
3. Challagundla P, Medeiros LJ, Kanagal-Shamanna R, et al. Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging. Am J Clin Pathol. 2014;142(6):837-844.
4. Mora A, Bosch R, Cuellar C, et al. CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2019;96(2):143-148.
5. Ranka R, Brahmbhatt B. Role of CD200 in differentiating chronic lymphocytic leukaemia from mantle cell lymphoma and comparing its expression across various B-cell chronic lymphoproliferative disorders. Int J Clin Diagn Pathol. 2020;3(3):27-31.
6. Osama A Ibrahim, Tawfik NM, Swify EM, et al. The role of CD200 in differentiating B-chronic lymphocytic leukemia from mantle cell lymphoma and its prognostic value. J Egypt Soc Haematol Res. 2013;9(2):39-44.
7. Hu Z, Sun Y, Schlette EJ, Tang G, Li S, Xu J, et al. CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Mod Pathol. 2018;31(2):327-336.
8. Sorigue M, Juncà J, Sarrate E, Grau J. Expression of CD43 in chronic lymphoproliferative leukemias. Cytometry B Clin Cytom. 2018;94(1):136-142.